93 related articles for article (PubMed ID: 26224247)
1. Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside.
Dorvignit D; García-Martínez L; Rossin A; Sosa K; Viera J; Hernández T; Mateo C; Hueber AO; Mesa C; López-Requena A
Immunobiology; 2015 Dec; 220(12):1343-50. PubMed ID: 26224247
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
3. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.
Casadesús AV; Fernández-Marrero Y; Clavell M; Gómez JA; Hernández T; Moreno E; López-Requena A
Glycoconj J; 2013 Oct; 30(7):687-99. PubMed ID: 23547010
[TBL] [Abstract][Full Text] [Related]
4. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody.
Fernández-Marrero Y; Hernández T; Roque-Navarro L; Talavera A; Moreno E; Griñán T; Vázquez AM; de Acosta CM; Pérez R; López-Requena A
Mol Immunol; 2011 Apr; 48(8):1059-67. PubMed ID: 21306777
[TBL] [Abstract][Full Text] [Related]
5. GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.
Labrada M; Dorvignit D; Hevia G; Rodríguez-Zhurbenko N; Hernández AM; Vázquez AM; Fernández LE
Semin Oncol; 2018 Jan; 45(1-2):41-51. PubMed ID: 30318083
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
7. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
Dohi T; Nores G; Hakomori S
Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
[TBL] [Abstract][Full Text] [Related]
8. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.
Fernández-Marrero Y; Roque-Navarro L; Hernández T; Dorvignit D; Molina-Pérez M; González A; Sosa K; López-Requena A; Pérez R; de Acosta CM
Immunobiology; 2011 Dec; 216(12):1239-47. PubMed ID: 21802167
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside.
Heinzelbecker J; Fauskanger M; Jonson I; Krengel U; Løset GÅ; Munthe L; Tveita A
Front Immunol; 2024; 15():1331345. PubMed ID: 38370401
[TBL] [Abstract][Full Text] [Related]
10. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
11. Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.
Piperno GM; López-Requena A; Predonzani A; Dorvignit D; Labrada M; Zentilin L; Burrone OR; Cesco-Gaspere M
Gene Ther; 2015 Dec; 22(12):960-7. PubMed ID: 26181624
[TBL] [Abstract][Full Text] [Related]
12. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
13. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
Nores GA; Dohi T; Taniguchi M; Hakomori S
J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
[TBL] [Abstract][Full Text] [Related]
14. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
15. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.
Rodríguez-Zhurbenko N; Martínez D; Blanco R; Rondón T; Griñán T; Hernández AM
Eur J Immunol; 2013 Mar; 43(3):826-37. PubMed ID: 23319307
[TBL] [Abstract][Full Text] [Related]
16. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
17. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity.
Roque-Navarro L; Chakrabandhu K; de León J; Rodríguez S; Toledo C; Carr A; de Acosta CM; Hueber AO; Pérez R
Mol Cancer Ther; 2008 Jul; 7(7):2033-41. PubMed ID: 18645013
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
Azuma Y; Ishikawa Y; Kawai S; Tsunenari T; Tsunoda H; Igawa T; Iida S; Nanami M; Suzuki M; Irie RF; Tsuchiya M; Yamada-Okabe H
Clin Cancer Res; 2007 May; 13(9):2745-50. PubMed ID: 17473208
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
20. Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.
Fernández-Marrero Y; López-Requena A
MAbs; 2011; 3(6):528-34. PubMed ID: 22123064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
